Therapeutic Strategies for the Management of HCV/HIV co-

最近在治疗和监测艾滋病毒-1感染方面取得的进展大大减少了与艾滋病毒有关的疾病和死亡率；然而，对艾滋病毒感染者的管理已变得越来越复杂。我们正在进行以下研究：(1)确定丙型肝炎病毒对聚乙二醇化干扰素治疗的反应的作用；(2)评估在管理艾滋病毒合并感染者中丙型肝炎病毒的新治疗策略；以及(3)开发新的基因组和蛋白质组标记，预测丙型肝炎病毒对现有和新的治疗方法的反应。对丙型肝炎/HIV混合感染者丙型肝炎治疗后病毒反应的动力学分析表明，根据血浆中丙型肝炎病毒水平的初始反应来预测抗丙型肝炎治疗的长期反应是可能的。在这些受试者中使用聚乙二醇化干扰素和利巴韦林的联合治疗，我们正在确定基因组和蛋白质标记是否可以在治疗开始前预测治疗的反应。另一项临床试验将确定更频繁剂量的聚乙二醇化干扰素与利巴韦林联合使用是否可以增强丙型肝炎感染者和艾滋病毒感染者对丙型肝炎治疗的病毒动力学反应。一项使用白蛋白结合干扰素α(Albuferon)治疗艾滋病毒感染患者中的丙型肝炎的新临床试验将于今年晚些时候开始登记。

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the management of HIV-infected patients has become increasingly complex. We are conducting studies that: (1) define the role of Hepatitis C viral response to pegylated interferon-based therapy (2) evaluate novel therapeutic strategies in the management of Hepatitis C virus among HIV co-infected individuals, and (3) develop novel genomic and proteomic markers that predict Hepatitis C viral response to existing and newer therapies. Analyses of the kinetics of the viral response to Hepatitis C therapy in Hepatitis C/HIV co-infected individuals suggest that it may be possible to predict long term response to anti-Hepatitis C therapy based on the initial response of the level of Hepatitis C virus in the plasma. Using combination therapy of pegylated interferon together with ribavirin in these subjects, we are determining whether genomic and proteomic markers can predict response to therapy prior to initiation of treatment. Another clinical trial will determine whether more frequent doses of pegylated interferon in combination with ribavirin can enhance the viral kinetic response to Hepatitis C therapy in persons with Hepatitis C infection and HIV infection. A new clinical trial using albumin-conjugated interferon alpha (Albuferon) to treat Hepatitis C among HIV infected patients will begin enrollment later this year.